Latest news with #Deuruxolitinib
&w=3840&q=100)
Business Standard
10 hours ago
- Business
- Business Standard
Sun Pharma gains on US launch of Leqselvi, analysts see strong upside
Sun Pharma rises 2.7% as it launches Leqselvi in US following settlement with Incyte, with analysts projecting $200-300 million revenue from the drug in 3-5 years Ram Prasad Sahu Listen to This Article India's largest drug maker, Sun Pharmaceutical Industries (Sun), gained 2.7 per cent on Tuesday and was the highest gainer among Sensex stocks. The gains followed the company's settlement and licence agreement with Incyte Corporation regarding litigation over its hair-loss drug, Leqselvi (Deuruxolitinib). Sun has now launched the specialty product in the US market. The settlement grants Sun a limited, non-exclusive licence to US patents covering the drug for non-oncology indications. This includes alopecia areata, an auto-immune disease that causes hair loss. While financial terms have not been disclosed, Sun will make an upfront payment and ongoing royalties to Incyte in
&w=3840&q=100)
Business Standard
a day ago
- Business
- Business Standard
Sun Pharma launches Leqselvi in US after patent settlement with Incyte Corp
Sun Pharmaceuticals on Monday announced the launch of hair loss drug Leqselvi (deuruxolitinib) in the United States (US) market for the treatment of alopecia areata, a condition in which the immune system attacks hair follicles, leading to hair loss on the scalp as well as other parts of the body. The announcement came after the Mumbai-based pharma major inked a settlement pact with US-based Incyte Corporation regarding the hair loss drug. Incyte had earlier accused Sun Pharma of patent infringement. Under the terms of the agreement, the parties will seek dismissal of the pending Leqselvi litigation in the United States District Court for the District of New Jersey. 'Incyte has also granted Sun a limited and non-exclusive licence to US patent numbers 9,662,335 and certain other related patents with respect to oral deuruxolitinib for certain agreed-upon non-haematology-oncology indications including alopecia areata, in the US,' the company said in a regulatory filing on the exchanges. The Mumbai-based pharma major will also pay Incyte an undisclosed upfront amount, plus ongoing royalty payments until the expiry of the patents, in exchange for the settlement and licence. Deuruxolitinib is expected to go off-patent in the financial year 2025–26 (FY26). The launch adds Leqselvi to Sun Pharma's innovative therapies portfolio, which saw sales of $1,216 million in FY25, according to Sun Pharma's investor presentation for the year. According to a Reuters report, Shrikant Akolkar, analyst at Nuvama Institutional Equities, said the drug could generate up to $400 million in sales by FY30, with peak sales potential of $900 million, and boost growth in Sun Pharma's key US market. Commenting on the launch, Sun Pharma America CEO Richard Ascroft said the launch of Leqselvi in the US brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them. 'As a company committed to launching new therapeutic options which address the unmet needs of patients, adding Leqselvi to our dermatology portfolio represents a key milestone for the business and an important advancement for the alopecia areata community,' he added. The announcement was made post market hours. On Monday, Sun Pharma's share rose marginally by 0.57 per cent, ending the day's trade at ₹1,682.05 apiece on the Bombay Stock Exchange (BSE).
Time of India
21-05-2025
- Business
- Time of India
Sun Pharma Q4 Preview: PAT may grow 6% YoY; domestic business to drive revenue
Pharma major Sun Pharma is likely to see high single-digit growth in its bottom line in the fourth quarter on the back of continued outperformance in the domestic business. According to an average estimate of five brokerages, revenue is expected to grow 9% year-on-year (YoY). Meanwhile, net profit for the reporting quarter will lag the revenue as an average of five estimates showed 6% YoY growth. Analysts are building in $500 million US sales in 4QFY25, primarily due to higher gRevlimid sales. Meanwhile, gross margins are seen declining 30 bps QoQ to 79.7% due to lower milestone income. For the specialty business, there is 20% YoY growth expectation at $325 million for 4Q owing to steady execution. Here's what brokerages expect from Sun Pharma's Q4 Kotak Equities We expect Sun Pharma's 4QFY25 overall sales to grow 8% YoY. For the global specialty business, we bake in a 17% QoQ sales decline to $308 million in 4QFY25, as specialty sales in 3QFY25 had inventory buildout and seasonality benefit. We build in a 9% YoY growth in India and a 9% YoY growth in RoW/EMs for 4QFY25. We expect Sun Pharma's 4QFY25 gross margins to decline 30 bps QoQ to 79.7% due to lower milestone income. We bake in R&D spends at 7.7% of sales in 4QFY25 (+150 bps QoQ). On the EBITDA front, we factor in a 12% YoY growth to Rs34.7 bn, with an EBITDA margin decline of 390 bps QoQ to 26.8% due to higher R&D spend. Motilal Oswal Expect DF sales to grow 13% YoY for the quarter. Clarity on the launch of Deuruxolitinib in the US market and watch out for the launch in other global markets. Factors to drive consistent growth in branded generics in emerging/ROW markets. Any further progress on products in Amplitude basket. YES Securities Revenue decline seen as Q3 had one-off milestone income in ROW markets coupled with sequential fall in domestic business. US to inch up 2% QoQ on likely better Taro numbers (based on historical pattern). Higher R&D vs Q3 to dampen margin QoQ. Nuvama We build Sun Pharma's revenue to grow by 9% YoY as domestic business continues its outperformance at 10%. We build US revenue at $503 million and global specialty business at $335 million, with dermatology product sales seeing improvement. R&D spend is expected to be at 6.4% of the sales. We estimate EBITDA/PAT to grow by 22%/4% YoY with EBITDA margins at 28.4% for Q4FY25. ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times)
Economic Times
21-05-2025
- Business
- Economic Times
Sun Pharma Q4 Preview: PAT may grow 6% YoY; domestic business to drive revenue
Pharma major Sun Pharma is likely to see high single-digit growth in its bottom line in the fourth quarter on the back of continued outperformance in the domestic business. According to an average estimate of five brokerages, revenue is expected to grow 9% year-on-year (YoY). ADVERTISEMENT Meanwhile, net profit for the reporting quarter will lag the revenue as an average of five estimates showed 6% YoY growth. Analysts are building in $500 million US sales in 4QFY25, primarily due to higher gRevlimid sales. Meanwhile, gross margins are seen declining 30 bps QoQ to 79.7% due to lower milestone income. For the specialty business, there is 20% YoY growth expectation at $325 million for 4Q owing to steady execution. We expect Sun Pharma's 4QFY25 overall sales to grow 8% YoY. For the global specialty business, we bake in a 17% QoQ sales decline to $308 million in 4QFY25, as specialty sales in 3QFY25 had inventory buildout and seasonality benefit. We build in a 9% YoY growth in India and a 9% YoY growth in RoW/EMs for 4QFY25. ADVERTISEMENT We expect Sun Pharma's 4QFY25 gross margins to decline 30 bps QoQ to 79.7% due to lower milestone income. We bake in R&D spends at 7.7% of sales in 4QFY25 (+150 bps QoQ). On the EBITDA front, we factor in a 12% YoY growth to Rs34.7 bn, with an EBITDA margin decline of 390 bps QoQ to 26.8% due to higher R&D spend. ADVERTISEMENT Expect DF sales to grow 13% YoY for the quarter. Clarity on the launch of Deuruxolitinib in the US market and watch out for the launch in other global markets. Factors to drive consistent growth in branded generics in emerging/ROW markets. Any further progress on products in Amplitude decline seen as Q3 had one-off milestone income in ROW markets coupled with sequential fall in domestic business. US to inch up 2% QoQ on likely better Taro numbers (based on historical pattern). Higher R&D vs Q3 to dampen margin QoQ. ADVERTISEMENT NuvamaWe build Sun Pharma's revenue to grow by 9% YoY as domestic business continues its outperformance at 10%. We build US revenue at $503 million and global specialty business at $335 million, with dermatology product sales seeing improvement. R&D spend is expected to be at 6.4% of the sales. We estimate EBITDA/PAT to grow by 22%/4% YoY with EBITDA margins at 28.4% for Q4FY25. ADVERTISEMENT (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
